BoxInterferences@uspto.gov Paper 25
703-308-9797
UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES
CHARLES H. HANNUM,
JANICE A. CULPEPPER, FRANK D. LEE, and DANIEL BIRNBAUM
(08/472,168 and 08/484,882),
Junior Party,
v.
IMMUNEX CORPORATION
(09/983,806 and 10/095,449),
Senior Party.
Interference No. 105,099
Before SCHAFER, TORCZON, and LANE, Administrative Patent Judges.
TORCZON, Administrative Patent Judge.
JUDGMENT ON HANNUM PRELIMINARY MOTION 1
(PURSUANT TO 37 CFR § 1.640)
INTRODUCTION
Hannum has filed Hannum preliminary motion 1 for judgment of no interference-
in-fact (Paper 23). Immunex neither joins nor opposes the motion (Paper 24). We
GRANT Hannum preliminary motion 1.
FINDINGS SUPPORTED BY A PREPONDERANCE OF THE EVIDENCE
[1] The interference involves a ligand for flt3, a tyrosine kinase receptor involved in
hematopoietic cell proliferation and differentiation. The ligand regulates the growth and
differentiation of hematopoietic progenitor and stem cells.1
1 S.D. Lyman & M.P. Beckmann, "Ligands for flt3 receptors", U.S. 2002/0107365 A1 at "Background
of the invention" (8 Aug. 2002) (the patent application publication for Immunex's involved 806 application)
[hereinafter exh ibit 3001].
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007